Comparative Pharmacology
Head-to-head clinical analysis: NORFLEX versus NORGESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORFLEX versus NORGESIC.
NORFLEX vs NORGESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orphenadrine is a centrally acting skeletal muscle relaxant with anticholinergic and local anesthetic properties. It acts primarily by blocking cholinergic receptors in the central nervous system, particularly in the reticular activating system, leading to reduced muscle spasm and rigidity.
NORGESIC is a combination of orphenadrine citrate, aspirin, and caffeine. Orphenadrine is a centrally acting muscle relaxant with anticholinergic properties; its exact mechanism is not fully understood, but it may act via central atropine-like effects and inhibition of reuptake of norepinephrine and serotonin. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, leading to analgesic, antipyretic, and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia via adenosine receptor antagonism.
Adults: 100 mg orally twice daily. Maximum dose: 200 mg/day.
1-2 tablets orally 2-4 times daily. Each tablet contains orphenadrine citrate 100 mg and acetaminophen 325 mg.
None Documented
None Documented
Terminal elimination half-life: 15-20 hours. Clinical context: Allows twice-daily dosing; steady-state reached in 3-5 days.
Terminal elimination half-life is 2–4 hours; clinical multiple dosing may require 4–6 hour intervals
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites; <10% unchanged in feces.
Primarily renal (70% as unchanged drug and metabolites; 10% as unchanged) and biliary (30%)
Category C
Category C
Muscle Relaxant
Muscle Relaxant